Combined intravitreal ranibizumab and verteporfin photodynamic therapy versus ranibizumab alone for the treatment of age-related macular degeneration | Zendy

Rosalia Giustolisi | Zendy; Nicoletta Fantozzi | Zendy; Mariateresa Staltari | Zendy; Jessica Marchiori | Zendy; Olga Mastrangelo | Zendy; Roberta Marcucci | Zendy; Federica Mirra | Zendy; Paola Mazzotta | Zendy; C. Balacco Gabrieli | Zendy; Type Diabetes TrialNet Study Group | Zendy

Open Access

Combined intravitreal ranibizumab and verteporfin photodynamic therapy versus ranibizumab alone for the treatment of age-related macular degeneration

Author(s) -

Rosalia Giustolisi,

Nicoletta Fantozzi,

Mariateresa Staltari,

Jessica Marchiori,

Olga Mastrangelo,

Roberta Marcucci,

Federica Mirra,

Paola Mazzotta,

C. Balacco Gabrieli,

Type Diabetes TrialNet Study Group

Publication year - 2011

Publication title -

digital journal of ophthalmology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.223

H-Index - 7

ISSN - 1542-8958

DOI - 10.5693/djo.01.2011.05.003

Subject(s) - ranibizumab , verteporfin , medicine , ophthalmology , macular degeneration , choroidal neovascularization , visual acuity , photodynamic therapy , randomized controlled trial , bevacizumab , surgery , chemotherapy , chemistry , organic chemistry

To compare same-day combined therapy of photodynamic therapy with verteporfin (PDT-V) and intravitreal ranibizumab versus monotherapy with ranibizumab for the treatment of choroidal neovascularization.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research